Penumbra Announces the European Launch of the Indigo® System With Lightning™ 7 and Lightning 12 Intelligent Aspiration
Retrieved on:
Thursday, April 14, 2022
Surgery, Medical Devices, Hospitals, Health, Cardiology, Code, Bleeding, CE marking, Contraindication, CAT7, Culture, U.S. Securities and Exchange Commission, COVID-19, Use, Twitter, Security (finance), Separator, Annual report, MD, Failure, Hospital, Thrombus, Patient, ICU, LinkedIn, Efficiency, Blood, Technology, Health, John Radcliffe Hospital, Pulmonary embolism, SEC, Embolism, NYSE, Investment, Physician, Multimedia, Risk, Indigo, Nature, Interior design, Birth control, Lightning
(NYSE: PEN), a global healthcare company focused on innovative therapies, announced that its Indigo Aspiration System with Lightning 7 and Lightning 12 have secured CE Mark (Conformit Europenne) and are now commercially available in Europe.
Key Points:
- (NYSE: PEN), a global healthcare company focused on innovative therapies, announced that its Indigo Aspiration System with Lightning 7 and Lightning 12 have secured CE Mark (Conformit Europenne) and are now commercially available in Europe.
- Both technologies are part of Penumbras Indigo Aspiration System now with Intelligent Aspiration for mechanical thrombectomy and are designed for single session arterial and venous thrombus removal, including the treatment of pulmonary embolisms.
- With Lightning, mechanical aspiration technology continues to advance to meet the needs of patients, which is our core purpose at Penumbra.
- The Indigo System with Lightning is an intelligent aspiration system powered by Penumbra ENGINE.